TrialBMJ open diabetes research & care2026

Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH.

Rafael Violante-Ortiz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.